Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's
Biogen (NASDAQ: BIIB) is recently down 3% in the premarket following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's. November weekly call option implied volatility is at 30, December is at 48; compared to its 52-week range of 28 to 45.